U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H40O4
Molecular Weight 392.5729
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHENODIOL

SMILES

C[C@]([H])(CCC(=O)O)[C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([H])(CC[C@]12C)[C@@]4(C)CC[C@]([H])(C[C@@]4([H])C[C@@]3([H])O)O

InChI

InChIKey=RUDATBOHQWOJDD-BSWAIDMHSA-N
InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H40O4
Molecular Weight 392.5729
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Chenodiol is the non-proprietary name for chenodeoxycholic acid, a naturally occurring human bile acid. It is a bitter-tasting white powder consisting of crystalline and amorphous particles freely soluble in methanol, acetone and acetic acid and practically insoluble in water. Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids. Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Chenodiol

Approved Use

Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment.

Launch Date

428198400000
Primary
URSODIOL

Approved Use

Ursodiol

Launch Date

616550400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.2 μM
15 mg/kg bw 1 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
URSODIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
49.8 μM × h
15 mg/kg bw 1 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
URSODIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 37-65
Health Status: unhealthy
Age Group: 37-65
Sex: M+F
Sources:
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea (1.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 1.7%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Inhibition 20 uM]
yes
no (co-administration study)
Comment: UDCA did not lead to detectable changes in midazolam pharmacokinetics
yes
weak (co-administration study)
Comment: UDCA modestly decreased digoxin disposition without
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue.
1998 Dec 25
Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury.
1999 Aug
Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
1999 Oct
Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants.
1999 Sep 24
Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor.
2000 Feb 15
Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease.
2000 Oct
Cetirizine-induce cholestasis.
2000 Oct
[Ursodeoxycholic acid as the main treatment of hepatobiliary diseases in children and teenagers].
2001
[Advances in the diagnosis and treatment of cholelithiasis].
2001
[Experience in treatment of chronic toxic hepatitis by ursodeoxicholic acid].
2001
Modulation of steady-state messenger RNA levels in the regenerating rat liver with bile acid feeding.
2001 Apr
Lichenoid eruptions due to ursodeoxycholic acid administration.
2001 Aug
Ursodeoxycholic acid causing exacerbation of dermatitis herpetiformis.
2001 Aug
Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant.
2001 Aug
Micronuclei induction, cell cycle delay and apoptosis as markers of cellular stress caused by ursodeoxycholic acid in human lymphocytes.
2001 Aug 22
Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid.
2001 Dec 14
No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study.
2001 Feb
The effect of ursodeoxycholic acid in children with prolonged hepatitis A virus infection that may be a trigger factor for autoimmune hepatitis.
2001 Feb
Management of drug-induced liver disease.
2001 Feb
Clinical studies with silymarin: fibrosis progression is the end point.
2001 Feb
Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group.
2001 Jan
Treatment of primary biliary cirrhosis.
2001 Jan-Dec
[Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity: a pilot study].
2001 Jan-Feb
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
2001 Jul
Fetal bile acid metabolism: analysis of urinary 3beta-monohydroxy-delta(5) bile acid in preterm infants.
2001 Jul
A case of autoimmune hepatitis with a high titer of antimitochondrial antibody and normal gamma-globulinemia.
2001 Jul
Prevention and treatment of veno-occlusive disease.
2001 Jul-Aug
Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
2001 Jun
[3 beta-Hydroxysteroid-delta 5-oxidoreductase/isomerase deficiency].
2001 Mar
Treatment of cholestasis and cholestatic disorders.
2001 Mar
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters.
2001 Mar
Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration.
2001 Mar
Characterization of primary pure cholesterol hepatolithiasis: cholangioscopic and selective cholangiographic findings.
2001 Mar
[Effects of bile acid preparations on DNA biosynthesis, apoptosis, and necrosis in hepatocytes in vitro].
2001 Mar-Apr
Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases.
2001 May
Synthetic bile acid derivatives induce nonapoptotic death of human retinal pigment epithelial cells.
2001 May
Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?
2001 May
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
2001 May
Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis.
2001 May
Effects of deoxycholic acid and its epimers on lipid peroxidation in isolated rat hepatocytes.
2001 May
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.
2001 May
Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases.
2001 May
[Correction of metabolic disturbances in patients with cholestasis].
2001 May-Jun
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
2001 Oct
The natural history of primary biliary cirrhosis: of genes and cooperation.
2001 Sep
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?
2001 Sep
Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids.
2001 Sep
Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression.
2001 Sep
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
2001 Sep
Biliary excretion of tauroursodeoxycholate-3-sulfate in the rat.
2001 Sep
Patents

Sample Use Guides

13 to 15 mg/kg/day administered in two to four divided doses with food
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:25 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:25 UTC 2021
Record UNII
0GEI24LG0J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHENODIOL
MI   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
3.ALPHA.,7.ALPHA.-DIHYDROXY-5.BETA.-CHOLAN-24-OIC ACID
Systematic Name English
CHENODEOXYCHOLIC ACID
EP   INN   MART.   VANDF   WHO-DD  
INN  
Official Name English
CHENODEOXYCHOLIC ACID [EP MONOGRAPH]
Common Name English
NSC-657949
Code English
CHENODEOXYCHOLIC ACID [MART.]
Common Name English
CHENODIOL [MI]
Common Name English
CHENODEOXYCHOLATE
Common Name English
CHENODIOL [USAN]
Common Name English
NSC-757798
Code English
ANTHROPODESOXYCHOLIC ACID
Common Name English
CHENODEOXYCHOLIC ACID [EP]
Common Name English
CHENODIOL [VANDF]
Common Name English
CHOLANORM
Brand Name English
CHENODEOXYCHOLIC ACID [INN]
Common Name English
CHENOFALK
Brand Name English
CHENIX
Brand Name English
CHENOCOL
Brand Name English
CHENODIOL [ORANGE BOOK]
Common Name English
CHOLAN-24-OIC ACID, 3,7-DIHYDROXY-, (3.ALPHA.,5.BETA.,7.ALPHA.)
Common Name English
CHENODEOXYCHOLIC ACID [JAN]
Common Name English
CHENDOL
Brand Name English
GALLODESOXYCHOLIC ACID
Common Name English
FLUIBIL
Brand Name English
CHENOSSIL
Brand Name English
URSODEOXYCHOLIC ACID IMPURITY A [EP]
Common Name English
CHENODESOXYCHOLIC ACID
Common Name English
CHENIC ACID
Common Name English
ANTHROPODODESOXYCHOLIC ACID
Common Name English
ANTHROPODEOXYCHOLIC ACID
Common Name English
CHENODEOXYCHOLIC ACID [WHO-DD]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 300510
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
LOINC 30519-3
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
NCI_THESAURUS C66913
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
EU-Orphan Drug EU/3/14/1406
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
FDA ORPHAN DRUG 175303
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
LOINC 2065-1
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
FDA ORPHAN DRUG 3384
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
LIVERTOX 186
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
FDA ORPHAN DRUG 235406
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
WHO-ATC A05AA01
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
WHO-VATC QA05AA01
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
Code System Code Type Description
CAS
474-25-9
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
FDA UNII
0GEI24LG0J
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
IUPHAR
608
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
PUBCHEM
10133
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
DRUG CENTRAL
4361
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
WIKIPEDIA
CHENODEOXYCHOLIC ACID
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
DRUG BANK
DB06777
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL240597
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
MERCK INDEX
M3324
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY Merck Index
RXCUI
42588
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
ALTERNATIVE
MESH
D002635
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
INN
4391
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
EPA CompTox
474-25-9
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
EVMPD
SUB07463MIG
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
NCI_THESAURUS
C65206
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-481-8
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
RXCUI
2323
Created by admin on Fri Jun 25 21:14:25 UTC 2021 , Edited by admin on Fri Jun 25 21:14:25 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
CDCA, had a half-maximal effective concentration (EC50) of 50 mMand 10 micromolar murine and human FXR, respectively (Fig. 1B). These concentrations are well within the physiologic intracellular range reported in vivo (11).
AGONIST
IC50
METABOLIC ENZYME -> SUBSTRATE
MINOR
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
MINOR
METABOLITE -> PARENT
IN VITRO
MINOR
PARENT -> METABOLITE
BILE
METABOLITE -> PARENT
IN VITRO
MAJOR
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC